Product spotlight

30
Nov

Human connective tissue mast cells

Human connective tissue mast cells A cellular model to better understand the underlying mechanisms of Injection Site Reactions (ISRs) and other severe allergic reactions. Mast cell culture assays are critical to better understand the kinetics and dynamics underlying inflammatory reactions. Genoskin’s team of experts has developed a method to grow connective tissue-type mast cells (CTMCs) derived from the peripheral blood
Read more
28
Oct

A unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin

The FlowSkin® platform : a unique ex vivo perfused human skin model to test pharmacokinetic and systemic administration in human skin When human tissue culture meets microfluidic technology, it leads to the first perfused human skin model ; an amazing platform to overcome the challenges of drug development and replace animal testing. Almost 10 years ago now, Genoskin developed the
Read more
4
Sep

Genoskin launches new offering: NativeSkin access

Genoskin launches new skin offering, NativeSkin® access, that increases accessibility to animal testing alternatives NativeSkin, the only ex vivo human skin model sold online, will be available to purchase daily at a key price point, making it easier to order even for larger volume sales Toulouse, France & Salem, MA, USA, September 1, 2020 - Genoskin, a biotechnology company developing ready-to-use human skin
Read more
25
Oct

Genoskin granted new patent on subcutaneous injection model

Genoskin granted a new patent on ex vivo subcutaneous injection model The French National Institute for Intellectual Property (INPI) granted Genoskin's latest patent on its unique ex vivo subcutaneous injection model, HypoSkin®. A boom in the subcutaneous biologics market Today, subcutaneous injection is one of the most common methods to deliver a drug into the human body. Its use has increased significantly
Read more
6
Sep

New study model for injectable anti-psoriasis drugs

New study model for injectable anti-psoriasis drugs A hi-tech psoriasis skin model to study drug efficacy To evaluate the efficacy of injectable anti-psoriasis drugs, the Genoskin team has designed a new test model that combines the InflammaSkin® and HypoSkin® technologies. Below you’ll find a proof-of-concept case study that illustrates the relevance of the new Hypo-InflammaSkin® model during efficacy studies of injectable
Read more
29
Mar

A unique human skin model to study subcutaneous injections

Ex vivo human skin model to predict toxicity and efficacy of subcutaneous drugs HypoSkin®: a unique ex vivo human skin model for subcutaneous injection testing Subcutaneous biologics market is an emerging area expanding at an impressive average growth rate of 7% to reach € 161 billion by 2024. To date, there is a lack of relevant in vitro biological models to
Read more